NHS Reverses NICE's Rejection of Ovarian Cancer Drug Through Price Negotiation

The NHS approved mirvetuximab soravtansine (Elahere) on June 4 after NICE initially recommended against funding it. The reversal suggests NHS England negotiated new commercial terms with manufacturer AbbVie, though pricing details remain confidential. The shift illustrates how health systems increasingly bypass traditional cost-effectiveness thresholds in rare cancers, raising questions about transparency in drug access decisions.